Private equity’s investments in healthcare have often struggled to meet expectations. Top-line growth and attractive exit multiples are elusive in a sector weighed down by legacy systems, labor costs, and regulatory complexity. The urgent question facing investors, operating partners, and portfolio company leaders is: How can we reinvigorate returns and unlock enterprise value? The article explores how AI is already making an impact in specific use cases in HealthTech and tech-enabled services.
Author: Abhay Panchal
The highest-paid gastroenterologist in New York City earns $980,900 per year, according to Medscape’s salary reporter tool. Here is what the five highest-paid gastroenterologists in New York City earn each year, their amount of experience and their practice setting.
Healio Gastroenterology and its collaborators unveiled the newest class of Disruptive Innovators Award recipients during the ACG Annual Meeting in Phoenix. Each honoree across nine categories embodies the heart of gastroenterology or hepatology, driving innovation and progress within the field. Readers — helped select these trailblazers, casting more than 3,500 votes to recognize those making the most significant impact among an outstanding lineup of physicians, researchers, influencers, organizations and industry leaders.
The booming market for at-home microbiome kits promises insights into digestion, disease risk, and even longevity—but leading gastroenterologists warn that the science hasn’t caught up with the marketing. Experts like Dr. Eamonn Quigley of Houston Methodist note that while gut bacteria clearly influence health, the field is still in its infancy: most of the variability between people remains unexplained. These tests—often costing $300–$500—aren’t FDA-regulated and provide reports comparing users’ microbes to a supposed “ideal,” leading to confusion and frustration for physicians and patients alike. Compounding concerns, many testing companies also sell supplements or probiotics tied to their results, creating conflicts…
Digital chronic-care leader Omada Health is set to begin prescribing GLP-1 weight-loss drugs nationwide in 2026, marking a major expansion of its obesity-care platform. The move follows White House deals with Eli Lilly and Novo Nordisk to lower drug prices, signaling broader public access. Omada’s GLP-1 program—already supporting over 100,000 members—combines prescribing with AI-driven coaching, nutrition guidance, and remote monitoring. New data show that 63% of members maintained or continued losing weight a year after stopping GLP-1s when paired with Omada’s behavior-change model.
New research from IRB Barcelona and CNAG uncovers how colorectal tumors build a powerful two-layer defense that shields them from the immune system. Through the hormone TGF-β, tumors block immune cells (T lymphocytes) from entering and expanding within the tumor—effectively turning the cancer “invisible” to treatment. The study, published in Nature Genetics, shows that when TGF-β is inhibited, immune cells can flood the tumor and reignite their attack. The team also identified osteopontin, a macrophage-derived protein, as a secondary suppressor, offering a new drug target that could complement immunotherapy. While direct TGF-β inhibitors carry toxicity risks, the researchers propose alternative…
A new national analysis has revealed just how common—and costly—unnecessary endoscopies for heartburn still are in the U.S. According to Motive Medical Intelligence, which analyzed over 100 million insurance claims from mid-2022 through mid-2024, nearly 11% of GERD visits led to upper endoscopy despite long-standing guidelines advising against it for uncomplicated reflux. The result: millions of avoidable procedures and hundreds of billions in wasted spending annually. Geographic disparities are striking — states like Maine and New Hampshire showed the lowest overuse, while Wyoming, Iowa, and Alaska ranked among the highest. Experts note that this reflects not only variations in practice…
Obesity is a chronic, relapsing disease with significant health and economic impacts. As obesity rates and new medication options rise, national societies have developed guidelines for high-quality pharmacologic care. AGA has introduced new quality indicators to define and benchmark best practices for the use of obesity medications. These indicators are supported by strong evidence, address care gaps, and may be submitted for inclusion in national quality payment programs.
CapsoVision has filed for FDA Breakthrough Device Designation for its CapsoCam UGI capsule endoscopy system — a swallowable camera designed to detect pancreatic ductal adenocarcinoma at earlier, treatable stages. Unlike traditional imaging or invasive endoscopy, the device offers a completely non-invasive, panoramic view of the duodenal papilla, where subtle structural changes may reveal pancreatic disease. If granted, the designation would fast-track collaboration with the FDA and accelerate clinical validation. With pancreatic cancer’s 5-year survival rate lingering near 10% and most diagnoses made too late for surgery, a screening capsule could mark a turning point in detection. CapsoVision’s platform already powers…
Gastroenterologists practicing in ASCs face significant financial pressure starting in 2026, due to a new Medicare payment model that cuts physician payments for procedures performed in both hospital outpatient and ASC settings, and boosts payments for the office setting.While converting to office-based endoscopy isn’t feasible for every practice, now is the time to understand what it would take and if it’s right for your situation. Neil Gupta, MD, MPH, FASGE, successfully transitioned to office-based endoscopy and offers key considerations to evaluate whether it could be a viable part of your long-term strategy under the new payment system.